Aquyre Biosciences provides tissue adequacy assessment thru tissue micro-architecture delineation and intracellular data acquisition.
Aquyre Biosciences provides tissue adequacy assessment thru tissue micro-architecture delineation and intracellular data acquisition. Its Full-Field Optical Coherence Tomography (FFOCT) offers en face (transverse), high resolution, 3D imaging of the tissue micro-architecture, at a resolution of 1μm. FFOCT also allows for depth exploration at different focal planes, without compromising 1μm resolution. While the company's Dynamic Cell Imaging (DCI) enhances the cellular contrast by capturing the residual microscopic intracellular activity and behaviors in freshly excised tissue, without staining or partially destroying the tissue.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 9, 2022 | Series Unknown | $5.42M | — | — | — | Detail |
Nov 15, 2021 | Series A | $17.14M | — | — | — | Detail |
Jul 10, 2021 | Series A | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
HealthTech Capital | — | Series A |